Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

Ponni Perumalswami, David E. Kleiner, Glen Lutchman, Theo Heller, Brian Borg, Yoon Park, T. Jake Liang, Jay H. Hoofnagle, Marc G. Ghany

Research output: Contribution to journalArticle

Abstract

Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is reported to be a risk factor for progression of fibrosis. The aims of this study were to evaluate the interactions between hepatic steatosis and fibrosis in a well-defined cohort of patients with CHC. The computerized pathology database at the National Institutes of Health Clinical Center was searched for patients with CHC who had undergone liver biopsy between 1980 and 2003. Biopsies were scored for necroinflammation using a modified histology activity index, fibrosis using the Ishak system, and steatosis as either none (25%). Four hundred ninety-four patients were identified. The mean age was 44 ± 9.8 years; 60% were male, 80% Caucasian, and 65% were infected with genotype 1. Steatosis was mild in 31% and moderate to severe in 9% of patients. In univariate analysis, steatosis was associated with increased age, body weight, body mass index (BMI), alanine aminotransferase (ALT) levels, histological necroinflammatory activity, and fibrosis. However, in multivariate analysis, steatosis was associated only with increased age, BMI, and ALT levels and not with fibrosis. One hundred thirty-six patients had 2 liver biopsies separated by 0.5 to 17 years. Worsening of fibrosis occurred in 40% of patients and correlated independently with increasing age, periportal necroinflammation, and ALT elevations but not with steatosis. In conclusion, in this cohort of patients with CHC, steatosis was associated with older age, higher BMI, and higher serum ALT levels but not with the presence of or subsequent progression of fibrosis.

Original languageEnglish (US)
Pages (from-to)780-787
Number of pages8
JournalHepatology
Volume43
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Fibrosis
Infection
Alanine Transaminase
Body Mass Index
Liver
Biopsy
National Institutes of Health (U.S.)
Histology
Multivariate Analysis
Genotype
Body Weight
Databases
Pathology
Serum

ASJC Scopus subject areas

  • Hepatology

Cite this

Perumalswami, P., Kleiner, D. E., Lutchman, G., Heller, T., Borg, B., Park, Y., ... Ghany, M. G. (2006). Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology, 43(4), 780-787. https://doi.org/10.1002/hep.21078

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. / Perumalswami, Ponni; Kleiner, David E.; Lutchman, Glen; Heller, Theo; Borg, Brian; Park, Yoon; Liang, T. Jake; Hoofnagle, Jay H.; Ghany, Marc G.

In: Hepatology, Vol. 43, No. 4, 04.2006, p. 780-787.

Research output: Contribution to journalArticle

Perumalswami, P, Kleiner, DE, Lutchman, G, Heller, T, Borg, B, Park, Y, Liang, TJ, Hoofnagle, JH & Ghany, MG 2006, 'Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection', Hepatology, vol. 43, no. 4, pp. 780-787. https://doi.org/10.1002/hep.21078
Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006 Apr;43(4):780-787. https://doi.org/10.1002/hep.21078
Perumalswami, Ponni ; Kleiner, David E. ; Lutchman, Glen ; Heller, Theo ; Borg, Brian ; Park, Yoon ; Liang, T. Jake ; Hoofnagle, Jay H. ; Ghany, Marc G. / Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. In: Hepatology. 2006 ; Vol. 43, No. 4. pp. 780-787.
@article{ae898888261d45ed90eba46550ce7090,
title = "Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection",
abstract = "Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is reported to be a risk factor for progression of fibrosis. The aims of this study were to evaluate the interactions between hepatic steatosis and fibrosis in a well-defined cohort of patients with CHC. The computerized pathology database at the National Institutes of Health Clinical Center was searched for patients with CHC who had undergone liver biopsy between 1980 and 2003. Biopsies were scored for necroinflammation using a modified histology activity index, fibrosis using the Ishak system, and steatosis as either none (25{\%}). Four hundred ninety-four patients were identified. The mean age was 44 ± 9.8 years; 60{\%} were male, 80{\%} Caucasian, and 65{\%} were infected with genotype 1. Steatosis was mild in 31{\%} and moderate to severe in 9{\%} of patients. In univariate analysis, steatosis was associated with increased age, body weight, body mass index (BMI), alanine aminotransferase (ALT) levels, histological necroinflammatory activity, and fibrosis. However, in multivariate analysis, steatosis was associated only with increased age, BMI, and ALT levels and not with fibrosis. One hundred thirty-six patients had 2 liver biopsies separated by 0.5 to 17 years. Worsening of fibrosis occurred in 40{\%} of patients and correlated independently with increasing age, periportal necroinflammation, and ALT elevations but not with steatosis. In conclusion, in this cohort of patients with CHC, steatosis was associated with older age, higher BMI, and higher serum ALT levels but not with the presence of or subsequent progression of fibrosis.",
author = "Ponni Perumalswami and Kleiner, {David E.} and Glen Lutchman and Theo Heller and Brian Borg and Yoon Park and Liang, {T. Jake} and Hoofnagle, {Jay H.} and Ghany, {Marc G.}",
year = "2006",
month = "4",
doi = "10.1002/hep.21078",
language = "English (US)",
volume = "43",
pages = "780--787",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

AU - Perumalswami, Ponni

AU - Kleiner, David E.

AU - Lutchman, Glen

AU - Heller, Theo

AU - Borg, Brian

AU - Park, Yoon

AU - Liang, T. Jake

AU - Hoofnagle, Jay H.

AU - Ghany, Marc G.

PY - 2006/4

Y1 - 2006/4

N2 - Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is reported to be a risk factor for progression of fibrosis. The aims of this study were to evaluate the interactions between hepatic steatosis and fibrosis in a well-defined cohort of patients with CHC. The computerized pathology database at the National Institutes of Health Clinical Center was searched for patients with CHC who had undergone liver biopsy between 1980 and 2003. Biopsies were scored for necroinflammation using a modified histology activity index, fibrosis using the Ishak system, and steatosis as either none (25%). Four hundred ninety-four patients were identified. The mean age was 44 ± 9.8 years; 60% were male, 80% Caucasian, and 65% were infected with genotype 1. Steatosis was mild in 31% and moderate to severe in 9% of patients. In univariate analysis, steatosis was associated with increased age, body weight, body mass index (BMI), alanine aminotransferase (ALT) levels, histological necroinflammatory activity, and fibrosis. However, in multivariate analysis, steatosis was associated only with increased age, BMI, and ALT levels and not with fibrosis. One hundred thirty-six patients had 2 liver biopsies separated by 0.5 to 17 years. Worsening of fibrosis occurred in 40% of patients and correlated independently with increasing age, periportal necroinflammation, and ALT elevations but not with steatosis. In conclusion, in this cohort of patients with CHC, steatosis was associated with older age, higher BMI, and higher serum ALT levels but not with the presence of or subsequent progression of fibrosis.

AB - Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is reported to be a risk factor for progression of fibrosis. The aims of this study were to evaluate the interactions between hepatic steatosis and fibrosis in a well-defined cohort of patients with CHC. The computerized pathology database at the National Institutes of Health Clinical Center was searched for patients with CHC who had undergone liver biopsy between 1980 and 2003. Biopsies were scored for necroinflammation using a modified histology activity index, fibrosis using the Ishak system, and steatosis as either none (25%). Four hundred ninety-four patients were identified. The mean age was 44 ± 9.8 years; 60% were male, 80% Caucasian, and 65% were infected with genotype 1. Steatosis was mild in 31% and moderate to severe in 9% of patients. In univariate analysis, steatosis was associated with increased age, body weight, body mass index (BMI), alanine aminotransferase (ALT) levels, histological necroinflammatory activity, and fibrosis. However, in multivariate analysis, steatosis was associated only with increased age, BMI, and ALT levels and not with fibrosis. One hundred thirty-six patients had 2 liver biopsies separated by 0.5 to 17 years. Worsening of fibrosis occurred in 40% of patients and correlated independently with increasing age, periportal necroinflammation, and ALT elevations but not with steatosis. In conclusion, in this cohort of patients with CHC, steatosis was associated with older age, higher BMI, and higher serum ALT levels but not with the presence of or subsequent progression of fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=33645979328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645979328&partnerID=8YFLogxK

U2 - 10.1002/hep.21078

DO - 10.1002/hep.21078

M3 - Article

C2 - 16557550

AN - SCOPUS:33645979328

VL - 43

SP - 780

EP - 787

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -